SWOG clinical trial number
CTSU/A031704
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Closed
Phase
Abbreviated Title
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Status Notes
Closed as of 5/15/2024.
Activated
05/09/2019
Closed
05/15/2024
Participants
CTSU
Research committees
Genitourinary Cancer
Treatment
Ipilimumab
Cabozantinib
Nivolumab
Eligibility Criteria Expand/Collapse
Please see eligibility criteria in protocol on www.CTSU.org.
Other Clinical Trials
SWOG Clinical Trial Number
S2427
Single Arm Phase II Study of Bladder Preservation with Immunoradiotherapy after a Clinically Meaningful Response to Neoadjuvant Therapy in Patients with Muscle Invasive Bladder Cancer (BRIGHT)
Research Committee(s)
Genitourinary Cancer
Activated
09/04/2025
Accrual
1%
Open
Phase
SWOG Clinical Trial Number
CCTG-PR26
A Randomized Phase III Clinical Trial for the Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (TRIPLE-SWITCH)
Research Committee(s)
Genitourinary Cancer
Activated
01/30/2025
Open
Phase
SWOG Clinical Trial Number
S2312
A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with metastatic castrate-resistant prostate cancer (mCRPC), Stratified by Aggressive Variant Signature
Research Committee(s)
Genitourinary Cancer
Activated
09/03/2024
Accrual
7%
Open
Phase